3SBio (TRSBF) Moat Score: 7/10 (As of Jul. 07, 2026)


TRSBF 3SBio Inc TRSBF
90 GF Score
Price $2.15
GF Value $1.61
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is 3SBio Moat Score?

3SBio TRSBF -2.27% 90 Moat Score is 7 as of Jul. 07, 2026. GuruFocus rates TRSBF with a GF Score™ of 90/100 and a GF Value™ of $1.61 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 1,394 Biotechnology companies, 3SBio ranks better than 99.57% on this metric.

3SBio has the Moat Score of 7, which implies that the company might have Wide Moat - Entry-level wide moat, clearly possessing durable advantages.

3SBio has Wide Moat: 3SBio Inc possesses a wide moat due to its valuable intellectual property and strong R&D capabilities. The company benefits from significant regulatory barriers and exclusive licenses in the biopharmaceutical sector, providing durable competitive advantages.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes 3SBio might have Wide Moat - Entry-level wide moat, clearly possessing durable advantages.

3SBio  (OTCPK:TRSBF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

3SBio Moat Score Related Terms

TRSBF vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, 3SBio's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

3SBio Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 3SBio's Moat Score distribution charts can be found below:

* The bar in red indicates where 3SBio's Moat Score falls into.


TRSBF
90GF Score
3SBio Inc TRSBF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 7 mean?
3SBio (TRSBF) has a Moat Score of 7 as of Jul. 07, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, 3SBio ranks #6 out of 1394 companies in the Biotechnology industry, placing it in the top 0.40000000000001%.
Is 3SBio's Moat Score too high?
3SBio's current Moat Score is 7. The Biotechnology industry median Moat Score is 2.00. 3SBio's value of 7 is 250% above this industry median. Based on the distribution chart, 3SBio ranks #6 out of 1394 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, 3SBio has a GF Score™ of 90/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 3SBio's Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, 3SBio ranks #6 out of 1394 companies for Moat Score. This places 3SBio in the top 0% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. 3SBio's value of 7 is 250% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,394 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 3SBio's current Moat Score of 7 is 250% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 3SBio's current Moat Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3SBio stock overvalued right now?
Based on GuruFocus' analysis, 3SBio (TRSBF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.61, compared to a current price of $2.15 — trading 33.5% above its estimated fair value. The current Moat Score is 7 and 250% above the Biotechnology industry median of 2.00. 3SBio's overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For 3SBio (TRSBF), the current Moat Score is 7 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 3SBio (TRSBF) Overvalued in 2026?

Based on GuruFocus' analysis, 3SBio stock appears to be overvalued. The current stock price of $2.15 is trading 33.5% above its estimated GF Value™ of $1.61. GuruFocus considers 3SBio to be Significantly Overvalued.

Key valuation signals for TRSBF:

  • Moat Score: 7
  • GF Value™: $1.61 vs. price of $2.15 (33.5% above fair value)
  • GF Score™: 90/100 with 1 warning sign
  • Industry Position: 250% above the Biotechnology median (#6 of 1394)

No single metric tells the full story. See the TRSBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

3SBio Business Description

Other Exchanges 01530:Hong Kong83B:Germany
Address No. 3 A1, Road 10, Shenyang Economy and Technology Development Zone, Shenyang, CHN
3SBio Inc is an investment holding company. It is a primary biotechnology company. The company is principally engaged in the development, production, marketing and sale of biopharmaceutical products in the People's Republic of China. The group has only one operating segment. It has presence in Chinese mainland, USA, Other countries/regions. The majority of revenue comes from USA. The core commercialized products of the group include several bio-pharmaceutical drugs, namely, TPIAO, recombinant human erythropoietin (rhEPO) products EPIAO and SEPO, Yisaipu and Cipterbin, and a small molecule drug, Mandi series of minoxidil drugs.
90GF Score

Get the complete analysis for TRSBF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.15
Price
$1.61
GF Value